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Antiretroviral is one of the drugs that 
extensively been studied for its drug-to- drug 
interaction. Its long term used and the fact that 
many HIV-infected patients came in the late stage 
of disease make polypharmacy is unavoidable.1 
Efavirenz is one of antiretroviral drugs that 
widely used in HIV-infected patients age more 
than 3 years old in many countries. Latest 
Indonesian antiretroviral guidelines recommend 
a combination of tenofovir, lamivudine and 
efavirenz given orally in one daily dose as 
the preferred primary fixed-drug combination 
treatment. This recommendation is based on 
many evidence supporting efficacy, tolerability, 
price, pregnancy safety, simplicity and the 
availability of the drug that will support the 
continuing comprehensive care for HIV-infected 
patients in primary care level.2
Since first being marketed in 1998, efavirenz 
has been dosed at 600 mg once a day for HIV-
infected adults, either as efavirenz tablet of 
fixed-drug combination.3 This drug often causes 
CNS-related symptoms that sometimes persist 
for a long period. This side effect frequently 
leads to treatment discontinuation or non-adhere 
to the treatment.
Efavirenz is extensively metabolized by the 
CYP2B2 isoenzyme group, particularly to the 
8OH-EFV metabolite. It is also an autoinducer 
of its own metabolism via induction of CYP2B6.4 
Earlier study in caucasian population shown 
that concomitant use of rifampicin could 
decrease efavirenz plasma concentration up to 
26%.5 Therefore, it was recommended to raise 
the dose to 800 mg a day in patients with pre 
treatment bodyweight more than 50 kg. Different 
finding was reported in South Africa. Study by 
Orell, et al.6 revealed that 600 mg efavirenz 
still retained adequate potency when giving 
concomitantly with rifampicin in HIV-infected 
patients with active tuberculosis.6 However, 
combining rifampicin with other available 
NNRTI nevirapine could decrease nevirapine 
plasma concentration even more.7 Therefore, 
efavirenz is still the preferred drug to be 
combined with rifampicin in many guidelines.2
Recently, questions have been raised about 
whether the dose of efavirenz could be reduced 
to 400 mg to lessen CNS-related effect and 
reduce cost without interfering the effectiveness. 
The ENCORE1 study first published in 2014 
randomly assigned 639 antiretroviral naive 
patients who were starting treatment to either 
400 mg or 600 mg efavirenz. About one third of 
participants in this study were Asian. Adverse 
events were significantly less frequent in the 
400 mg group, recovery of CD4 lymphocytes 
was better in the 400 mg group, and proportions 
of patients with viral load suppression at 48 
weeks were similar in both groups. HIV-infected 
patients with active tuberculosis were excluded 
in this study, hence it is unable to clarify the 
issue concomitant use of rifampicin with low 
dose efavirenz.8 However, the newest WHO 
has started to recommend the use of 400 mg 
efavirenz as alternative first-line regiment in 
combination with tenofovir and lamivudine/or 
emtricitabine.9
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This  recommendat ion needs  to  be 
implemented carefully for Indonesian population. 
Study reported here by Mariana, et al10 comparing 
HIV-infected Indonesian patients starting 
efavirenz-based antiretroviral therapy with 
and without the use of rifampicin revealed 
that there was large proportion of patients 
with sub-therapeutic efavirenz concentrations 
even in patients not receiving rifampicin. One 
of the plausible reasons is the possibility of 
many extensive metabolizer genotype in this 
population. Even though, in Indonesia, no studies 
have identified the CYP2B6 enzyme activity.
The impact of different therapeutic level 
of efavirenz to virological success can not be 
concluded in this study. Not only because of the 
small sample size, but also because of various 
time of viral load testing in defining the virologic 
suppression used in this study.10
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